Charlie Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual intensive outpatient mental health treatment for adolescents and young adults, Bozeman MT, raised $55M+. Addresses crisis-level care gaps via virtual IOP.
About
Charlie Health is a Bozeman, Montana-based virtual mental health company founded in 2020 that provides intensive outpatient program (IOP) care for adolescents, young adults, and families experiencing mental health crises. The company has raised over $55 million and targets the significant care gap between inpatient psychiatric hospitalization and standard outpatient therapy — a level of care that has historically been difficult to access, particularly outside major urban centers.\n\nCharlie Health's virtual IOP model delivers nine or more hours of structured group and individual therapy per week through a telehealth platform, allowing clients to receive high-intensity care from home while maintaining school or work routines. The clinical approach combines dialectical behavior therapy (DBT), cognitive behavioral therapy (CBT), and trauma-informed care, with treatment teams including licensed therapists, psychiatrists, and care coordinators. Programs are designed for adolescents aged 11 to 17 and young adults aged 18 to 26 presenting with depression, anxiety, trauma, self-harm, and suicidality.\n\nThe company accepts insurance from most major carriers, a deliberate strategic choice to reach underserved populations who cannot afford self-pay intensive treatment. Charlie Health's telehealth delivery model gives it geographic reach into rural and suburban communities where brick-and-mortar IOPs are scarce, positioning the company as an infrastructure solution for the adolescent mental health crisis that intensified during the COVID-19 pandemic.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.